This is a two stage study. Firstly a dose escalation step is used to define the best dose for
the drug combination, using the rolling 6 design where up to 6 patients are recruited at each
dose level, and increasing the dose of one or other agent according to the side effects of
treatment. An initial dose escalation phase was completed where 25 patients were enrolled,
using the study treatment combination of PD-0325901 with PF-02341066. Following
discontinuation of the MEKi (inihibitor), PD-0325901, the study was updated to include a
further dose escalation phase using the new combination study treatment, MEKi, Binimetinib
with METi, PF-02341066. The effects of this drug combination will be assessed to define the
recommended dose level for the dose expansion phase of the study.
Second the new drug combination is observed in 42-98 patients with bowel cancer for its
efficacy and tolerability. Patients who give consent will have their archival tumour samples
tested for RAS and c-MET status.
Potential participants will, after giving consent, undergo screening tests to ensure that it
is safe for them to take part. These involve a detailed medical history, physical exam, blood
tests, ophthalmology exam, ECG and ultrasound and skin biopsies. The size and extent of
tumours is also assessed by CT and/or MRI scan.
For the initial dose escalation phase, on assurance that the test results are satisfactory,
patients start on PD-0325901 first for one week. On Day -7 a physical exam, ECG and blood
test is performed, with a repeat blood test on Day -6. End of first week PD samples of blood
are taken to observe the level of PD-0325901. Day 1 PF-02341066 is introduced after further
clinical safety assessments. There are further blood samples taken over 24 hours to measure
levels of PD-0325901 and PF-02341066 on days 21 and 28 of the first cycle.
For the further dose escalation phase, again assuming that the screening test results are
satisfactory, patients start on Day 1 with the combined treatment of PF-02341066 with
Binimetinib. A physical exam, ECG and blood test is performed, with a repeat blood test on
Day 2. There are further blood samples taken over 24 hours to measure levels of Binimetinib
and PF-02341066 on day 21of the first cycle.
Patients have weekly visits when side effects are reviewed and a physical examination is
performed. On Day 15 a second skin biopsy is taken along with blood tests to assess liver and
renal function. At the end of the first 4 weeks cycle, for the initial dose escalation phase,
and at end of 8 weeks for the new combination therapy dose escalation phase, an ophthalmology
exam is compared with the baseline assessment.
For subsequent cycles in both the initial dose escalation and further dose escalation phases,
visits remain weekly and include safety assessments as per Day 1. Blood levels of PD-0325901
or Binimetinib and PF-02341066 are measured on day 21 of even numbered cycles. In addition
the tumour size is checked every second cycle, and the study treatment stopped if the tumour
continues to grow.
When patients stop taking the study treatment they will be reviewed after 4 weeks for any
side effects and have a physical examination and other safety tests performed.
For patients entering the expansion phase of the trial the procedures are similar, except
that there is a pre-screening stage where tumour biopsies are required. Patients will have a
sample of their tumour assessed, following consent, to determine their RAS and cMET status.
This may involve a fresh biopsy. If suitable, the patient will be entered into the screening
for the dose expansion phase and a fresh tumour biopsy may be taken if not already done so.
The study schedule is the same as for the escalation phase using Binimetinib with
PF-02341066. At the end of treatment a further, optional, tumour biopsy may be taken.
After trial participation patients will be offered further care with the trial team or their
referring oncology team as appropriate.
INCLUSION CRITERIA (Inclusion criteria for the completed initial dose escalation phase
using PF-02341066/PD-0325901 are listed in Appendix 7.) All patients
- Age ≥ 16 years (>18 years in France)
- ECOG performance status 0-1 (Appendix 1)
- Adequate respiratory function on clinical assessment
- Left ventricular ejection fraction (LVEF) ≥ 50% as determined by a multigated
acquisition (MUGA) scan or echocardiogram┼
- Able to give informed consent prior to any screening procedures being performed and be
capable of complying with the protocol and its requirements
- Haematological and biochemical indices within the ranges shown below:
- Haemoglobin (Hb) ≥ 9g/dl (transfusion to achieve this allowed ),
- Neutrophils ≥ 1,500/μl,
- Platelet count ≥ 100,000/μl,
- AST or ALT ≤ 2.5 x ULN, patient with liver metastases ≤ 5 × ULN,
- Alkaline phosphatase ≤ 5 x ULN,
- Serum Bilirubin ≤ 1.5 x ULN,
- Creatinine Clearance ≥ 50ml/min (Calculated by Cockcroft Gault equation, or by EDTA)
(Appendix 2)
- Able to swallow oral medication
- Life expectancy of at least 3 months.
Dose escalation phase:
- Patients with any advanced solid tumours
- Patients for whom the combination of PF-02341066 with Binimetinib is a reasonable
option.
Dose expansion phase:
Patients will be eligible for pre-screening for this phase provided that:
- They have given informed consent to screening.
- They are willing to undergo a biopsy for assessment of tumour RAS mutation status and
c-MET assessment.
- The Investigator anticipates that they are likely to satisfy the eligibility criteria
for the trial. Formal screening should not be performed until the tumour pre-screening
result is known.
Eligibility for the trial, in patients passing pre-screening, requires:
- Histologically confirmed colorectal adenocarcinoma that is either a) RASMT (KRAS codon
12, 13, 61, 117, 146; NRAS codon 12, 13, 61, 117, 146) or b) RASWT/c-MET
mutated/amplified or c) RASWT/c-MET over-expressed with progressive disease on or
within 6 months of completion of adjuvant therapy or after chemotherapy and/or
targeted therapies for metastatic disease.
- Prior treatment with an EGFR targeted monoclonal antibody for patients with
RASWT/c-MET mutated or amplified CRC or c) RASWT/c-MET over-expressed CRC.
- No evidence for a mutation in BRAF at codon600
- Metastases accessible for biopsy on 2-3 occasions
- At least one other measurable lesion (according to RECIST v1.1).
- Unsuitable for potential curative resection. ┼For non-UK territories: if
echocardiogram (ECHO) cannot be performed, a MUGA scan may be performed in compliance
with local policy, applicable national legislation and relevant approvals. Cardiac
ejection fraction must be determined as measured by ECHO in the UK.
EXCLUSION CRITERIA (Exclusion criteria for the completed initial dose escalation phase
using PF-02341066/PD-0325901 are listed in Appendix 7.) All patients
- Unstable ischaemic heart disease, cardiac dysrhythmias, coronary/peripheral artery
bypass graft or cerebrovascular accident within 6 months prior to starting treatment.
- Uncontrolled arterial hypertension despite medical treatment.
- Ongoing congestive heart failure or cardiac dysrhythmias of NCI CTCAE Grade ≥2 or
uncontrolled atrial fibrillation.
- History of extensive disseminated/bilateral or known presence of Grade 3 or 4
interstitial fibrosis or interstitial lung disease, including a history of
pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung
disease (ILD), obliterative bronchiolitis, and pulmonary fibrosis. A history of prior
radiation pneumonitis is allowed.
- Any active central nervous system (CNS) lesion (i.e., those with radiographically
unstable, symptomatic lesions) and/or leptomeningeal metastases. However, patients
treated with stereotactic radiotherapy or surgery are eligible if the patient remained
without evidence of CNS disease progression ≥ 3 months. Patients must be off
corticosteroid therapy for ≥ 3 weeks.
- Patients who have neuromuscular disorders that are associated with elevated CK (e.g.,
inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal
muscular atrophy);
- Patients who are planning on embarking on a new strenuous exercise regimen after first
dose of study treatment. NB: Muscular activities, such as strenuous exercise, that can
result in significant increases in plasma CK levels should be avoided while on
Binimetinib treatment
- Spinal cord compression unless treated with the patient attaining good pain control
and stable or recovered neurologic function.
- Carcinomatous meningitis or leptomeningeal disease.
- History of hypoalbuminaemia, or patients with peritoneal disease or pleural disease,
where there is a requirement for ascitic or pleural taps.
- History of retinal vein occlusion, intraocular pressure > 21 mmHg or patient
considered at risk of retinal vein thrombosis (e.g. history of hyperviscosity or
hypercoagulability syndromes).
- History of retinal degenerative disease.
- History of Gilbert's syndrome.
- Active infections (including chronic hepatitis type B or C and HIV infection if status
known), severe immunologic defect, compromised bone marrow function.
- Other severe acute or chronic medical (including severe gastro-intestinal disorders
e.g. partial bowel obstruction, malabsorption, active inflammatory bowel disease) or
psychiatric conditions or laboratory abnormalities that the investigator considers
would make the patient a poor trial candidate, would impart excess risk associated
with study participation or drug administration or could interfere with protocol
compliance or the interpretation of trial results.
- Patients who have undergone major surgery ≤ 3 weeks prior to starting study drug or
who have not recovered from side effects of such procedure.
- Use of drugs or foods that are known potent CYP3A4 inhibitors or inhibitors or are
CYP3A4 substrates with narrow therapeutic indices (see Appendix 5).
- Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or
chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C)
and four weeks for investigational medicinal products before treatment. Patients with
prostate cancer may continue to receive endocrine therapy to maintain castrate levels
of androgens.
- Resting ECG with QTc > 480msec at 2 or more time points within a 24h period (using
Fredericia correction).
- Requirement for medication known to prolong QT interval (Appendix 5).
- History of other malignancy less than 3 years before the diagnosis of current cancer,
EXCLUDING the following: Non-melanoma skin cancer, in situ carcinoma of the cervix
treated surgically with curative intent, other malignant tumours that have been
treated curatively and patient is deemed disease-free
- Women with the ability to become pregnant (or already pregnant or lactating). However,
those female patients who have a negative serum pregnancy test before enrolment and
agree to use one highly effective form of contraception (oral, injected or implanted
hormonal contraception or intra-uterine device) in addition to condom plus spermicide
for four weeks before entering the trial, during the trial and for six months
afterwards are considered eligible.
- Male patients with partners of child-bearing potential unless they agree to take
measures not to father children by using one form of highly effective contraception
including oral, injected or implanted hormonal contraception or intra-uterine device
in addition to condom plus spermicide, during the trial and for six months
afterwards). Men with pregnant or lactating partners should be advised to use barrier
method contraception (condom plus spermicidal gel) to prevent exposure to the foetus
or neonate.
- Prior exposure to any of a HGF, cMET or a MEK inhibitor.
